Twist Bioscience

Thesis

Twist Bioscience (NASDAQ: TWST) trades at ~$50, with a ~$3B market cap. Revenue of $392M is growing 17% YoY and the company is approaching EBITDA breakeven. A significant milestone for a biotech company that has been in growth mode. Twist is a synthetic biology tools company, providing DNA synthesis and sequencing to researchers and industry. The most interesting catalyst is the Atlas Data Storage spinoff. Twist spun off its DNA data storage division with $155M in seed financing, the most well-funded DNA storage company ever. Twist retains a minority stake, creating embedded optionality. DNA data storage addresses a massive eventual market as global data creation outpaces storage capacity growth. $392M in revenue with 17% growth and approaching breakeven represents genuine commercial traction. This is not a pre-revenue bet. The synbio tools business is more defensive than the product companies that failed (Bolt Threads, Amyris), as Twist sells picks and shovels to the sector. At $3B market cap, Twist is a mid-cap biotech with real revenue, real growth, and a free call option on DNA data storage through its Atlas stake.

Catalysts

• +Atlas Data Storage spinoff with $155M seed financing. Twist retains minority stake
• +Approaching EBITDA breakeven on $392M revenue growing 17% YoY
• +Picks-and-shovels position in synbio. Benefits from sector growth regardless of which companies win

Risks

• -At $3B market cap, limited 'undiscovered' upside compared to smaller opportunities
• -DNA data storage (Atlas) is still pre-commercial. May take years to generate revenue
• -Synbio sector sentiment remains depressed after multiple high-profile failures

Common questions